Array BioPharma
Boulder
About Array BioPharma
Array BioPharma is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company partnered drugs are binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology), and tucatinib (partnered with Cascadian Therapeutics). The company is committed to providing therapies to patients. Array BioPharma was founded on 1998 and is headquartered in Boulder, Colorado.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $412.1M
- Funding stage: M&A
- Last round: Post-IPO Equity (Sep 2017)
- Ticker: nasdaq:ARRY
- Website: arraybiopharma.com
- Phone: 303.381.6600
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/array-biopharma-160388 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.